White Papers

White Paper Download


What It Means for Your Business – and What’s Needed for a Successful Implementation

Consensus is building around the idea that greater access to patient-level clinical data is a good thing – good for science, business and humanity. From a business perspective, pooling data can significantly reduce the cost of drug development while improving the efficiency of clinical trials. It can also lower clinical trial costs by reducing the number of patients needed for new studies. But data sharing and transparency raises new issues and brings a host of new questions, benefits and risks. For example, unless appro­priate safeguards are in place, open access to clinical trial data could compromise patient privacy, enable faulty science, and be a resource-intensive burden for trial sponsors and data stewards. This paper discusses different approaches to successfully implementing clinical trial data transparency while mitigating these risks.

Have a SAS profile? Log in to pre-fill the form.

*  First Name
*  Last Name
*  E-mail Address
* Organization/Company
* Industry
* Job Title
*  Country
State/Province/Territory
(Required for Canada and U.S.)
* Business Phone
Yes, I would like to opt-in to receive occasional emails from SAS and its affiliates
about SAS events, free white papers, special offers on training and publications, etc.
All personal information will be handled in accordance with the SAS Privacy Statement.


( * indicates required field )